RECORDATI FINALISE L'ACQUISITION DE ORPHAN EUROPE

Milan, le 13 décembre 2007 - Recordati annonce la finalisation de l'acquisition de Orphan Europe, groupe pharmaceutique spécialisé dans les maladies rares, annoncée le 28 septembre dernier, suite à l'autorisation de l'Autorité chargée de la concurrence. L'accord se chiffre à 135 millions d'euros.


Orphan Europe, dont le siège est à Paris, est un groupe pharmaceutique européen spécialisé dans le développement, le dépôt de marque, le marketing et la distribution de médicaments uniques pour le traitement des maladies rares et orphelines. Orphan Europe compte 120 employés, a des filiales dans 9 pays européens ainsi qu'aux Emirats Arabes Unis et des bureaux dans 7 pays. Sales for the full year 2006 were E 40 million with EBIT of E 7.6 million. The company's net financial position is positive.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,200. A European field force of over 1,100 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2006 was E 576.2 million, operating income was E 120.3 million and net income was E 74.0 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: [email protected]

Media Relations
Claudio Rossetti (Echo Comunicazione d'Impresa)
(39)02 62694736
e-mail: [email protected]

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
VIA M. CIVITALI, 1 - 20148 MILANO, ITALY - TEL (39) 02 48787.1 - FAX (39) 02 40073747

Copyright Hugin